The EULAR Annual European Congress of Rheumatology meeting was held in London from June 8-11, 2016 and was well attended by thousands. This year’s meeting had over 2,000 poster displays, and the EULAR 2016 Congress presented new recommendations on the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia.
All News
The impact of systemic glucocorticoid exposure on fracture risk among new-onset rheumatoid arthritis (RA) was studied using administrative claims data detailing the treatments and outcomes of 42,127 newly diagnosed RA patients (between 2005-2012).
Sjogren's syndrome is a highly prevalent disorder, affecting women ten times more frequently than men. Although the typical onset follows menopause, a minority of women may develop primary Sjogren’s syndrome (pSS) during child-bearing years.
Dr. Jack Cush reviews the news, reports and highlights from EULAR and the last 2 weeks from RheumNow.com.
Recognizing that formalized training in telemedicine is not widely offered to physicians-in-training, the American Medical Association (AMA) adopted policy during its Annual Meeting aimed at ensuring medical students and residents learn how to use telemedicine in clinical practice.
The combined analysis of 130,315 rheumatoid arthritis patients from 11 European registries did not reveal an association between invasive (malignant) melanoma and the use of biologic therapies.
Men and women with arthritis have nearly a two-fold higher prevalence of lifetime suicide attempts than those without arthritis, according to a recent study from the University of Toronto.
Blocking the type 1 interferon receptor with the monoclonal antibody anifrolumab shows promise as a treatment for moderate-to-severe systemic lupus erythematosus (SLE), according to a phase IIb study presented here.
Prescription of long-acting opioids for chronic noncancer pain was associated with an increased risk of all-cause mortality, including deaths from causes other than overdose, compared with anticonvulsants or cyclic antidepressants, according to a study appearing in the June 14 issue of JAMA.
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
A retrospective observational study of over 6000 patients with primary hyperparathyroidism (PHPT), followed in the Kaiser-Permanente system, has shown a greater need for parathyroidectomy than was previously thought.
Lancet has published the results of the U-ACT-early study assessing the efficacy of monotherapy versus combination therapy using an interleukin-6 receptor-blocking monoclonal antibody, tocilizumab, in patients with rheumatoid arthritis.
The NEJM today published the results of two phase-3 trials (UNCOVER-2 and UNCOVER-3) demonstrating the efficacy of ixekizumab (a monoclonal antibody against interleukin-17A) in the treatment of moderate-to-severe psoriasis.
The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.
JAMA has reported the results of an 18-year National Inpatient Sample, a database of US non-federal hospitalizations.
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA).
Methotrexate , a cornerstone drug used to treat rheumatoid arthritis, has led to 90 hospitalizations and 7 deaths according to a recent report from the Medical Journal of Australia.
The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid arthritis and psoriatic disease.
In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.
